by Madaline Spencer | Jan 30, 2026
The US Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of adults with newly diagnosed multiple myeloma (MM) who are ineligible for...
by Madaline Spencer | Jan 30, 2026
Hartmut Döhner, MD, Professor of Medicine and Medical Director of the Department of Hematology and Oncology, Ulm University, Germany, discusses bleximenib combination therapy for treatment of patients with acute myeloid leukemia (AML). AML is a cancer...
by Madaline Spencer | Jan 29, 2026
Raffi Tachdjian, MD, Associate Clinical Professor of Medicine & Pediatrics, Division of Allergy & Clinical Immunology, University of California Los Angeles, discusses a new formulation of Orladeyo (berotralstat) for the treatment of pediatric patients with...
by Madaline Spencer | Jan 28, 2026
The US Food and Drug Administration (FDA) has approved the expanded indication of Cerezyme (imiglucerase) for the treatment of non-neuronal symptoms in adult and pediatric patients with Gaucher disease (GD) type 3. GD refers to a group of inherited metabolic diseases...
by Madaline Spencer | Jan 27, 2026
Data from the Phase 2b CORAL trial of nalbuphine extended release (ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) was recently published in the Journal of the American Medical Association (JAMA). IPF is a rare, progressive...
